title: Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation.
abstract: Identifying targets of dysregulated microRNAs (miRNAs) will enhance our understanding of how altered miRNA expression contributes to the malignant phenotype of breast cancer. The expression of miR-205 was reduced in four breast cancer cell lines compared to the normal-like epithelial cell line MCF10A and in tumor and metastatic tissues compared to adjacent benign breast tissue. Two predicted binding sites for miR-205 were identified in the 3' untranslated region of the high mobility group box 3 gene, HMGB3. Both dual-luciferase reporter assay and Western blotting confirmed that miR-205 binds to and regulates HMGB3. To further explore miR-205 targeting of HMGB3, WST-1 proliferation and in vitro invasion assays were performed in MDA-MB-231 and BT549 cells transiently transfected with precursor miR-205 oligonucleotide or HMGB3 small interfering RNA (siRNA). Both treatments reduced the proliferation and invasion of the cancer cells. The mRNA and protein levels of HMGB3 were higher in the tumor compared to adjacent benign specimens and there was an indirect correlation between the expression of HMGB3 mRNA and patient survival. Treatment of breast cancer cells with 5-Aza/TSA derepressed miR-205 and reduced HMGB3 mRNA while knockdown of the transcriptional repressor NRSF/REST, reduced miR-205 and increased HMGB3. In conclusion, regulation of HMGB3 by miR-205 reduced both proliferation and invasion of breast cancer cells. Our findings suggest that modulating miR-205 and/or targeting HMGB3 are potential therapies for advanced breast cancer.
authors.affiliation: College of Pharmacy, the Ohio State University, Columbus, Ohio, United States of America.
authors.forename: Ola A
authors.initials: OA
authors.lastname: Elgamal
authors.forename: Jong-Kook
authors.initials: JK
authors.lastname: Park
authors.forename: Yuriy
authors.initials: Y
authors.lastname: Gusev
authors.forename: Ana Clara P
authors.initials: AC
authors.lastname: Azevedo-Pouly
authors.forename: Jinmai
authors.initials: J
authors.lastname: Jiang
authors.forename: Avtar
authors.initials: A
authors.lastname: Roopra
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Schmittgen
mesh_terms: D020413:3' Untranslated Regions; D001374:Azacitidine / Q000494:pharmacology; D020029:Base Pairing; D001483:Base Sequence; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002843:Chromatin / Q000378:metabolism; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D055785:Gene Knockdown Techniques; D025765:HMGB3 Protein / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D009361:Neoplasm Invasiveness; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism; D000099229:RE1-Silencing Transcription Factor
chemical_list: D020413:3' Untranslated Regions; D001374:Azacitidine; D002843:Chromatin; D025765:HMGB3 Protein; D035683:MicroRNAs; D012097:Repressor Proteins; D025521:Tumor Suppressor Proteins; D000099229:RE1-Silencing Transcription Factor; C534425:MIR205, human